

ASTCT Pharmacy SIG Journal Club Session

June 5, 2024

2-3 PM CDT

TARGET AUDIENCE

This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

PROGRAM OVERVIEW

This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the June Journal Club session, Drs. Krajewski and Sowell will present two articles related to:

- a. Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation, and
- b. Gilteritinib as post-transplant maintenance for acute myeloid leukemia.

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

- Review impact of FMS-like tyrosine kinase 3 (FLT3) mutation on prognosis and treatment of acute myeloid leukemia (AML)
- Evaluate efficacy and safety of gilteritinib as post-transplant maintenance for AML with FLT3-internal tandem duplication (ITD) mutation
- Identify patients who are most likely to benefit from post-transplant gilteritinib maintenance
- Review cytomegalovirus (CMV) infection prophylaxis strategies following hematopoietic stem cell transplant (HSCT)
- Analyze the efficacy and safety of extended duration letermovir prophylaxis following HSCT in patients at risk of CMV infection
- Explore the utility of extended duration letermovir for CMV prophylaxis following HSCT

FACULTY & ARTICLES

Kristyn Krajewski, PharmD

PGY-2 Pharmacy Resident

Hospital at the University of Pennsylvania

Article: [Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3](#)

Hunter Sowell, PharmD

PGY-2 Pharmacy Resident

Vanderbilt University Medical Center

Article: [Efficacy and safety of extended duration letermovir prophylaxis in recipients of hematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial](#)

Instructions for Participation and Requesting Credit

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.

Credit Fulfillment

- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days.

ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION

Pharmacists



This knowledge-based activity, UAN JA0007204-9999-24-060-L01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. **Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date.** Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures

The individuals listed below disclosed the following relevant financial relationships:

Name of Individual	Individual's Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	NA	NA
Elizabeth Eubanks	Reviewer	1. Medexus Pharmaceuticals, Inc., Dedham Group	1. Non-CE Consulting	The following relationships were mitigated by: <ul style="list-style-type: none">• Medexus Pharmaceuticals ended 5/25/22• Dedham Group ended 3/24/23
Haedyn Smith	ASTCT Staff	No relevant financial disclosures	NA	NA
Hunter Sowell, PharmD	Faculty	No relevant financial disclosures	NA	NA
Jamie Ziggas	ASTCT Reviewer	No relevant financial disclosures	NA	NA
Kristyn Krajewski, PharmD	Faculty	No relevant financial disclosures	NA	NA
Olivia White	ASTCT Reviewer	No relevant financial disclosures	NA	NA
Shikha Patel, PharmD, BCPS	Faculty	No relevant financial disclosures	NA	NA
Timothy Porter	ASTCT Journal Club Coordinator	1. Medexus Pharmaceuticals, Inc.	1. Non-CE Consulting	The following relationship was mitigated by: <ul style="list-style-type: none">• Medexus Pharmaceuticals ended in June 2022

DISCLOSURE OF UNLABELED USE

TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label

use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

CONTACT INFORMATION

If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.